epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
Atacicept
atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
Avasopasem
avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Rubraca

rucaparib

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Adult Dosing .

Dosage forms:  TAB: 200 mg, 250 mg, 300 mg

Special Note

[uses, dosing may vary]
Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

BRCA-mutated ovarian CA, maintenance tx

[600 mg PO bid]
Info: for patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal CA

BRCA-mutated prostate CA, metastatic castration-resistant

[600 mg PO bid]
Info: for patients who have received prior tx with androgen deprivation therapy; use with GnRH analog in patients without bilateral orchiectomy

renal dosing

[see below]
CrCl >30: no adjustment; CrCl <30: not defined
HD/PD: not defined

hepatic dosing

[see below]
bilirubin 1-3x ULN or AST >ULN: no adjustment; bilirubin >3x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@1e0737f7
  • hypersensitivity to drug or ingredient
  • incomplete hematologic toxicity recovery after prior chemo use
  • avoid: breastfeeding during tx and x2wk after D/C
  • avoid: semen donation during tx and x3mo after D/C
  • avoid: sun exposure
  • avoid: UV light exposure, artificial
  • caution: patients of childbearing potential
  • caution: male patients of reproductive potential
  • caution: electrolyte abnormalities
  • caution: long QT syndrome, congenital
  • caution: QT prolongation
  • caution: QT prolongation family history
  • caution: torsades de pointes history
  • caution: ventricular arrhythmia
  • caution: bradycardia
  • caution: MI, recent
  • caution: CHF

Drug Interactions .

Overview

rucaparib

PARP inhibitor

Interaction Characteristics:
  • CYP1A2 inhibitor, moderate
  • CYP2C9 inhibitor, weak
  • CYP2C19 inhibitor, weak
  • CYP3A4 inhibitor, weak
  • BCRP inhibitor
  • P-gp inhibitor, weak
  • immunomodulatory effects
  • myelosuppressive oncologic agent
  • photosensitivity
  • prolongs QT interval (known)

Contraindicated

  • adenovirus vaccine, live
  • Rubraca (rucaparib)
    +
    adenovirus vaccine, live
    1 interaction

    Contraindicated

    rucaparib + adenovirus vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • chikungunya vaccine, live
  • Rubraca (rucaparib)
    +
    chikungunya vaccine, live
    1 interaction

    Contraindicated

    rucaparib + chikungunya vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • cholera vaccine, live
  • Rubraca (rucaparib)
    +
    cholera vaccine, live
    1 interaction

    Contraindicated

    rucaparib + cholera vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • colchicine
  • Rubraca (rucaparib)
    +
    colchicine
    1 interaction

    Contraindicated

    rucaparib + colchicine

    CV RISK REDUCTION: monitor CBC; consider monitoring CK, myopathy s/sx; GOUT OR FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, use alternative or monitor CBC; consider decr. colchicine dose during and x14 days after rucaparib use: combo may incr. colchicine levels, risk of myelosuppression, myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • dengue vaccine, live
  • Rubraca (rucaparib)
    +
    dengue vaccine, live
    1 interaction

    Contraindicated

    rucaparib + dengue vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • domperidone
  • Rubraca (rucaparib)
    +
    domperidone
    1 interaction

    Contraindicated

    rucaparib + domperidone

    contraindicated: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • dronedarone
  • Rubraca (rucaparib)
    +
    dronedarone
    1 interaction

    Contraindicated

    rucaparib + dronedarone

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • eliglustat
  • Rubraca (rucaparib)
    +
    eliglustat
    1 interaction

    Contraindicated

    rucaparib + eliglustat

    CYP2D6 EM: contraindicated if Child-Pugh Class A and if also combined w/ moderate or strong CYP2D6 inhibitor; if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 IM: if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • fezolinetant
  • Rubraca (rucaparib)
    +
    fezolinetant
    1 interaction

    Contraindicated

    rucaparib + fezolinetant

    contraindicated: combo may incr. fezolinetant levels, risk of adverse effects (hepatic metabolism inhibited)

  • influenza nasal vaccine, live
  • Rubraca (rucaparib)
    +
    influenza nasal vaccine, live
    1 interaction

    Contraindicated

    rucaparib + influenza nasal vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • levoketoconazole
  • Rubraca (rucaparib)
    +
    levoketoconazole
    1 interaction

    Contraindicated

    rucaparib + levoketoconazole

    contraindicated: combo may incr. levoketoconazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • measles/mumps/rubella vaccine, live
  • Rubraca (rucaparib)
    +
    measles/ mumps/ rubella vaccine, live
    1 interaction

    Contraindicated

    rucaparib + measles/ mumps/ rubella vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • pimozide
  • Rubraca (rucaparib)
    +
    pimozide
    1 interaction

    Contraindicated

    rucaparib + pimozide

    contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • rotavirus vaccine, live
  • Rubraca (rucaparib)
    +
    rotavirus vaccine, live
    1 interaction

    Contraindicated

    rucaparib + rotavirus vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • smallpox vaccine, live
  • Rubraca (rucaparib)
    +
    smallpox vaccine, live
    1 interaction

    Contraindicated

    rucaparib + smallpox vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • thioridazine
  • Rubraca (rucaparib)
    +
    thioridazine
    1 interaction

    Contraindicated

    rucaparib + thioridazine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • typhoid vaccine, live
  • Rubraca (rucaparib)
    +
    typhoid vaccine, live
    1 interaction

    Contraindicated

    rucaparib + typhoid vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • varicella vaccine, live
  • Rubraca (rucaparib)
    +
    varicella vaccine, live
    1 interaction

    Contraindicated

    rucaparib + varicella vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

  • yellow fever vaccine, live
  • Rubraca (rucaparib)
    +
    yellow fever vaccine, live
    1 interaction

    Contraindicated

    rucaparib + yellow fever vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response, increase risk of disseminated infection (immunosuppressive effects)

Avoid/Use Alternative

  • adagrasib
  • Rubraca (rucaparib)
    +
    adagrasib
    1 interaction

    Avoid/Use Alternative

    rucaparib + adagrasib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • alosetron
  • Rubraca (rucaparib)
    +
    alosetron
    1 interaction

    Avoid/Use Alternative

    rucaparib + alosetron

    use alternative: combo may incr. alosetron levels, risk of adverse effects (hepatic metabolism inhibited)

  • alpelisib
  • Rubraca (rucaparib)
    +
    alpelisib
    1 interaction

    Avoid/Use Alternative

    rucaparib + alpelisib

    use alternative: combo may incr. alpelisib levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)

  • alprazolam
  • Rubraca (rucaparib)
    +
    alprazolam
    1 interaction

    Avoid/Use Alternative

    rucaparib + alprazolam

    use alternative or monitor respiratory rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • aminolevulinic acid topical
  • Rubraca (rucaparib)
    +
    aminolevulinic acid topical
    1 interaction

    Avoid/Use Alternative

    rucaparib + aminolevulinic acid topical

    avoid combo: combo may incr. risk of photosensitivity reaction (additive effects)

  • amiodarone
  • Rubraca (rucaparib)
    +
    amiodarone
    1 interaction

    Avoid/Use Alternative

    rucaparib + amiodarone

    use alternative or monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • anagrelide
  • Rubraca (rucaparib)
    +
    anagrelide
    1 interaction

    Avoid/Use Alternative

    rucaparib + anagrelide

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • apalutamide
  • Rubraca (rucaparib)
    +
    apalutamide
    1 interaction

    Avoid/Use Alternative

    rucaparib + apalutamide

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • apixaban
  • Rubraca (rucaparib)
    +
    apixaban
    1 interaction

    Avoid/Use Alternative

    rucaparib + apixaban

    ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

  • apomorphine
  • Rubraca (rucaparib)
    +
    apomorphine
    1 interaction

    Avoid/Use Alternative

    rucaparib + apomorphine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • arsenic trioxide
  • Rubraca (rucaparib)
    +
    arsenic trioxide
    1 interaction

    Avoid/Use Alternative

    rucaparib + arsenic trioxide

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • artemether/lumefantrine
  • Rubraca (rucaparib)
    +
    artemether/ lumefantrine
    1 interaction

    Avoid/Use Alternative

    rucaparib + artemether/ lumefantrine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • asenapine
  • Rubraca (rucaparib)
    +
    asenapine
    1 interaction

    Avoid/Use Alternative

    rucaparib + asenapine

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • azithromycin
  • Rubraca (rucaparib)
    +
    azithromycin
    1 interaction

    Avoid/Use Alternative

    rucaparib + azithromycin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • bedaquiline
  • Rubraca (rucaparib)
    +
    bedaquiline
    1 interaction

    Avoid/Use Alternative

    rucaparib + bedaquiline

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • bendamustine
  • Rubraca (rucaparib)
    +
    bendamustine
    1 interaction

    Avoid/Use Alternative

    rucaparib + bendamustine

    consider alternatives: combo may incr. bendamustine levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • bosentan
  • Rubraca (rucaparib)
    +
    bosentan
    1 interaction

    Avoid/Use Alternative

    rucaparib + bosentan

    avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise, caution advised: combo may incr. bosentan levels, risk of adverse effects (hepatic metabolism inhibited)

  • cabozantinib
  • Rubraca (rucaparib)
    +
    cabozantinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + cabozantinib

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ceritinib
  • Rubraca (rucaparib)
    +
    ceritinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + ceritinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • chloramphenicol
  • Rubraca (rucaparib)
    +
    chloramphenicol
    1 interaction

    Avoid/Use Alternative

    rucaparib + chloramphenicol

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • chloroquine
  • Rubraca (rucaparib)
    +
    chloroquine
    1 interaction

    Avoid/Use Alternative

    rucaparib + chloroquine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • citalopram
  • Rubraca (rucaparib)
    +
    citalopram
    1 interaction

    Avoid/Use Alternative

    rucaparib + citalopram

    use alternative or monitor ECG; adjust max citalopram dose to 20 mg/day: combo may incr. citalopram levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • cladribine oral
  • Rubraca (rucaparib)
    +
    cladribine oral
    1 interaction

    Avoid/Use Alternative

    rucaparib + cladribine oral

    use alternative or monitor CBC: combo may incr. cladribine levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport inhibited, additive effects)

  • clarithromycin
  • Rubraca (rucaparib)
    +
    clarithromycin
    1 interaction

    Avoid/Use Alternative

    rucaparib + clarithromycin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clofazimine
  • Rubraca (rucaparib)
    +
    clofazimine
    1 interaction

    Avoid/Use Alternative

    rucaparib + clofazimine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • codeine
  • Rubraca (rucaparib)
    +
    codeine
    1 interaction

    Avoid/Use Alternative

    rucaparib + codeine

    use alternative or monitor respiratory rate, consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, may incr. production of active metabolite morphine)

  • crizotinib
  • Rubraca (rucaparib)
    +
    crizotinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + crizotinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dabigatran
  • Rubraca (rucaparib)
    +
    dabigatran
    1 interaction

    Avoid/Use Alternative

    rucaparib + dabigatran

    ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport inhibited)

  • deferiprone
  • Rubraca (rucaparib)
    +
    deferiprone
    1 interaction

    Avoid/Use Alternative

    rucaparib + deferiprone

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • degarelix
  • Rubraca (rucaparib)
    +
    degarelix
    1 interaction

    Avoid/Use Alternative

    rucaparib + degarelix

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • desflurane
  • Rubraca (rucaparib)
    +
    desflurane
    1 interaction

    Avoid/Use Alternative

    rucaparib + desflurane

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • desipramine
  • Rubraca (rucaparib)
    +
    desipramine
    1 interaction

    Avoid/Use Alternative

    rucaparib + desipramine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmedetomidine
  • Rubraca (rucaparib)
    +
    dexmedetomidine
    1 interaction

    Avoid/Use Alternative

    rucaparib + dexmedetomidine

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmedetomidine injection
  • Rubraca (rucaparib)
    +
    dexmedetomidine injection
    1 interaction

    Avoid/Use Alternative

    rucaparib + dexmedetomidine injection

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexrazoxane
  • Rubraca (rucaparib)
    +
    dexrazoxane
    1 interaction

    Avoid/Use Alternative

    rucaparib + dexrazoxane

    monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use, otherwise avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

  • disopyramide
  • Rubraca (rucaparib)
    +
    disopyramide
    1 interaction

    Avoid/Use Alternative

    rucaparib + disopyramide

    use alternative or monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • dofetilide
  • Rubraca (rucaparib)
    +
    dofetilide
    1 interaction

    Avoid/Use Alternative

    rucaparib + dofetilide

    use alternative or monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • donepezil
  • Rubraca (rucaparib)
    +
    donepezil
    1 interaction

    Avoid/Use Alternative

    rucaparib + donepezil

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dordaviprone
  • Rubraca (rucaparib)
    +
    dordaviprone
    1 interaction

    Avoid/Use Alternative

    rucaparib + dordaviprone

    use alternative or monitor ECG, electrolytes; separate admin.: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • droperidol
  • Rubraca (rucaparib)
    +
    droperidol
    1 interaction

    Avoid/Use Alternative

    rucaparib + droperidol

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • efavirenz
  • Rubraca (rucaparib)
    +
    efavirenz
    1 interaction

    Avoid/Use Alternative

    rucaparib + efavirenz

    consider alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • encorafenib
  • Rubraca (rucaparib)
    +
    encorafenib
    1 interaction

    Avoid/Use Alternative

    rucaparib + encorafenib

    use alternative or monitor ECG, electrolytes: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ensartinib
  • Rubraca (rucaparib)
    +
    ensartinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + ensartinib

    avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)

  • entrectinib
  • Rubraca (rucaparib)
    +
    entrectinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + entrectinib

    avoid combo: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ephedra
  • Rubraca (rucaparib)
    +
    ephedra
    1 interaction

    Avoid/Use Alternative

    rucaparib + ephedra

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • epirubicin
  • Rubraca (rucaparib)
    +
    epirubicin
    1 interaction

    Avoid/Use Alternative

    rucaparib + epirubicin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • eribulin
  • Rubraca (rucaparib)
    +
    eribulin
    1 interaction

    Avoid/Use Alternative

    rucaparib + eribulin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • erythromycin
  • Rubraca (rucaparib)
    +
    erythromycin
    1 interaction

    Avoid/Use Alternative

    rucaparib + erythromycin

    use alternative or monitor ECG: combo may incr. erythromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • etrasimod
  • Rubraca (rucaparib)
    +
    etrasimod
    1 interaction

    Avoid/Use Alternative

    rucaparib + etrasimod

    consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

  • fexinidazole
  • Rubraca (rucaparib)
    +
    fexinidazole
    1 interaction

    Avoid/Use Alternative

    rucaparib + fexinidazole

    if possible, do not initiate fexinidazole until 5 half-lives after rucaparib D/C; use alternative or monitor CBC, ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression; may decr. fexinidazole active metabolite levels, efficacy (additive effects; hepatic metabolism inhibited, decr. conversion to active metabolites)

  • flecainide
  • Rubraca (rucaparib)
    +
    flecainide
    1 interaction

    Avoid/Use Alternative

    rucaparib + flecainide

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fluorouracil
  • Rubraca (rucaparib)
    +
    fluorouracil
    1 interaction

    Avoid/Use Alternative

    rucaparib + fluorouracil

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fluoxetine
  • Rubraca (rucaparib)
    +
    fluoxetine
    1 interaction

    Avoid/Use Alternative

    rucaparib + fluoxetine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • foscarnet
  • Rubraca (rucaparib)
    +
    foscarnet
    1 interaction

    Avoid/Use Alternative

    rucaparib + foscarnet

    use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

  • fosfomycin injection
  • Rubraca (rucaparib)
    +
    fosfomycin injection
    1 interaction

    Avoid/Use Alternative

    rucaparib + fosfomycin injection

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

  • ganciclovir
  • Rubraca (rucaparib)
    +
    ganciclovir
    1 interaction

    Avoid/Use Alternative

    rucaparib + ganciclovir

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • gepotidacin
  • Rubraca (rucaparib)
    +
    gepotidacin
    1 interaction

    Avoid/Use Alternative

    rucaparib + gepotidacin

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • gilteritinib
  • Rubraca (rucaparib)
    +
    gilteritinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + gilteritinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • givinostat
  • Rubraca (rucaparib)
    +
    givinostat
    1 interaction

    Avoid/Use Alternative

    rucaparib + givinostat

    use alternative or monitor CBC, ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

  • glasdegib
  • Rubraca (rucaparib)
    +
    glasdegib
    1 interaction

    Avoid/Use Alternative

    rucaparib + glasdegib

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • goserelin
  • Rubraca (rucaparib)
    +
    goserelin
    1 interaction

    Avoid/Use Alternative

    rucaparib + goserelin

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • grapefruit
  • Rubraca (rucaparib)
    +
    grapefruit
    1 interaction

    Avoid/Use Alternative

    rucaparib + grapefruit

    use alternative or monitor ECG w/ large amounts of grapefruit (>1L juice): combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • haloperidol
  • Rubraca (rucaparib)
    +
    haloperidol
    1 interaction

    Avoid/Use Alternative

    rucaparib + haloperidol

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • histrelin
  • Rubraca (rucaparib)
    +
    histrelin
    1 interaction

    Avoid/Use Alternative

    rucaparib + histrelin

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • hydrocodone
  • Rubraca (rucaparib)
    +
    hydrocodone
    1 interaction

    Avoid/Use Alternative

    rucaparib + hydrocodone

    use alternative or monitor respiratory rate, ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day; consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of QT prolongation, cardiac arrhythmias, CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

  • hydroxychloroquine
  • Rubraca (rucaparib)
    +
    hydroxychloroquine
    1 interaction

    Avoid/Use Alternative

    rucaparib + hydroxychloroquine

    use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

  • hydroxyzine
  • Rubraca (rucaparib)
    +
    hydroxyzine
    1 interaction

    Avoid/Use Alternative

    rucaparib + hydroxyzine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ibutilide
  • Rubraca (rucaparib)
    +
    ibutilide
    1 interaction

    Avoid/Use Alternative

    rucaparib + ibutilide

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • iloperidone
  • Rubraca (rucaparib)
    +
    iloperidone
    1 interaction

    Avoid/Use Alternative

    rucaparib + iloperidone

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • inotuzumab ozogamicin
  • Rubraca (rucaparib)
    +
    inotuzumab ozogamicin
    1 interaction

    Avoid/Use Alternative

    rucaparib + inotuzumab ozogamicin

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • isoflurane
  • Rubraca (rucaparib)
    +
    isoflurane
    1 interaction

    Avoid/Use Alternative

    rucaparib + isoflurane

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ivabradine
  • Rubraca (rucaparib)
    +
    ivabradine
    1 interaction

    Avoid/Use Alternative

    rucaparib + ivabradine

    consider alternative or monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ivosidenib
  • Rubraca (rucaparib)
    +
    ivosidenib
    1 interaction

    Avoid/Use Alternative

    rucaparib + ivosidenib

    use alternative or monitor ECG, electrolytes: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • lefamulin
  • Rubraca (rucaparib)
    +
    lefamulin
    1 interaction

    Avoid/Use Alternative

    rucaparib + lefamulin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • leuprolide
  • Rubraca (rucaparib)
    +
    leuprolide
    1 interaction

    Avoid/Use Alternative

    rucaparib + leuprolide

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • levofloxacin
  • Rubraca (rucaparib)
    +
    levofloxacin
    1 interaction

    Avoid/Use Alternative

    rucaparib + levofloxacin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lofexidine
  • Rubraca (rucaparib)
    +
    lofexidine
    1 interaction

    Avoid/Use Alternative

    rucaparib + lofexidine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lonafarnib
  • Rubraca (rucaparib)
    +
    lonafarnib
    1 interaction

    Avoid/Use Alternative

    rucaparib + lonafarnib

    use alternative or monitor HR, ECG, electrolytes, CBC: combo may incr. lonafarnib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • loperamide
  • Rubraca (rucaparib)
    +
    loperamide
    1 interaction

    Avoid/Use Alternative

    rucaparib + loperamide

    use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lopinavir/ritonavir
  • Rubraca (rucaparib)
    +
    lopinavir/ ritonavir
    1 interaction

    Avoid/Use Alternative

    rucaparib + lopinavir/ ritonavir

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • macimorelin
  • Rubraca (rucaparib)
    +
    macimorelin
    1 interaction

    Avoid/Use Alternative

    rucaparib + macimorelin

    avoid combo, allowing sufficient washout time before diagnostic test: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • meperidine
  • Rubraca (rucaparib)
    +
    meperidine
    1 interaction

    Avoid/Use Alternative

    rucaparib + meperidine

    use alternative or monitor respiratory rate, ECG: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • methadone
  • Rubraca (rucaparib)
    +
    methadone
    1 interaction

    Avoid/Use Alternative

    rucaparib + methadone

    use alternative or monitor respiratory rate, ECG; consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • mifepristone
  • Rubraca (rucaparib)
    +
    mifepristone
    1 interaction

    Avoid/Use Alternative

    rucaparib + mifepristone

    use alternative or monitor ECG if daily mifepristone use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • milsaperidone
  • Rubraca (rucaparib)
    +
    milsaperidone
    1 interaction

    Avoid/Use Alternative

    rucaparib + milsaperidone

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • mobocertinib
  • Rubraca (rucaparib)
    +
    mobocertinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + mobocertinib

    use alternative or monitor ECG, electrolytes: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • moxifloxacin
  • Rubraca (rucaparib)
    +
    moxifloxacin
    1 interaction

    Avoid/Use Alternative

    rucaparib + moxifloxacin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • neratinib
  • Rubraca (rucaparib)
    +
    neratinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + neratinib

    avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • nilotinib
  • Rubraca (rucaparib)
    +
    nilotinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + nilotinib

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • oliceridine
  • Rubraca (rucaparib)
    +
    oliceridine
    1 interaction

    Avoid/Use Alternative

    rucaparib + oliceridine

    use alternative or monitor respiratory rate, ECG: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ondansetron
  • Rubraca (rucaparib)
    +
    ondansetron
    1 interaction

    Avoid/Use Alternative

    rucaparib + ondansetron

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • osimertinib
  • Rubraca (rucaparib)
    +
    osimertinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + osimertinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • oxaliplatin
  • Rubraca (rucaparib)
    +
    oxaliplatin
    1 interaction

    Avoid/Use Alternative

    rucaparib + oxaliplatin

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • oxycodone
  • Rubraca (rucaparib)
    +
    oxycodone
    1 interaction

    Avoid/Use Alternative

    rucaparib + oxycodone

    use alternative or monitor respiratory rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • ozanimod
  • Rubraca (rucaparib)
    +
    ozanimod
    1 interaction

    Avoid/Use Alternative

    rucaparib + ozanimod

    consider alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pacritinib
  • Rubraca (rucaparib)
    +
    pacritinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + pacritinib

    avoid combo: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

  • palifermin
  • Rubraca (rucaparib)
    +
    palifermin
    1 interaction

    Avoid/Use Alternative

    rucaparib + palifermin

    avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo; otherwise, caution advised: combo may incr. severity and duration of oral mucositis (antagonistic effects)

  • paliperidone
  • Rubraca (rucaparib)
    +
    paliperidone
    1 interaction

    Avoid/Use Alternative

    rucaparib + paliperidone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • palonosetron
  • Rubraca (rucaparib)
    +
    palonosetron
    1 interaction

    Avoid/Use Alternative

    rucaparib + palonosetron

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pasireotide
  • Rubraca (rucaparib)
    +
    pasireotide
    1 interaction

    Avoid/Use Alternative

    rucaparib + pasireotide

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pazopanib
  • Rubraca (rucaparib)
    +
    pazopanib
    1 interaction

    Avoid/Use Alternative

    rucaparib + pazopanib

    avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (BCRP-mediated transport inhibited, additive effects)

  • penicillamine
  • Rubraca (rucaparib)
    +
    penicillamine
    1 interaction

    Avoid/Use Alternative

    rucaparib + penicillamine

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pentamidine
  • Rubraca (rucaparib)
    +
    pentamidine
    1 interaction

    Avoid/Use Alternative

    rucaparib + pentamidine

    use alternative or monitor ECG, CBC; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

  • phenobarbital
  • Rubraca (rucaparib)
    +
    phenobarbital
    1 interaction

    Avoid/Use Alternative

    rucaparib + phenobarbital

    avoid combo if neonatal seizure use; otherwise, monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pimavanserin
  • Rubraca (rucaparib)
    +
    pimavanserin
    1 interaction

    Avoid/Use Alternative

    rucaparib + pimavanserin

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pirfenidone
  • Rubraca (rucaparib)
    +
    pirfenidone
    1 interaction

    Avoid/Use Alternative

    rucaparib + pirfenidone

    avoid combo if also combined w/ mod-strong CYP2C9, CYP2C19, CYP2D6, or CYP2E1 inhibitor; otherwise, consider alternative or decr. pirfenidone dose to 534 mg tid: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metabolism inhibited)

  • pitolisant
  • Rubraca (rucaparib)
    +
    pitolisant
    1 interaction

    Avoid/Use Alternative

    rucaparib + pitolisant

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ponesimod
  • Rubraca (rucaparib)
    +
    ponesimod
    1 interaction

    Avoid/Use Alternative

    rucaparib + ponesimod

    use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

  • porfimer
  • Rubraca (rucaparib)
    +
    porfimer
    1 interaction

    Avoid/Use Alternative

    rucaparib + porfimer

    avoid combo: combo may incr. risk of photosensitivity reaction (additive effects)

  • pralsetinib
  • Rubraca (rucaparib)
    +
    pralsetinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + pralsetinib

    use alternative or monitor ECG, consider monitoring electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd or 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • primaquine
  • Rubraca (rucaparib)
    +
    primaquine
    1 interaction

    Avoid/Use Alternative

    rucaparib + primaquine

    use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

  • procainamide
  • Rubraca (rucaparib)
    +
    procainamide
    1 interaction

    Avoid/Use Alternative

    rucaparib + procainamide

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • propafenone
  • Rubraca (rucaparib)
    +
    propafenone
    1 interaction

    Avoid/Use Alternative

    rucaparib + propafenone

    if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, use alternative or monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited, additive effects)

  • quetiapine
  • Rubraca (rucaparib)
    +
    quetiapine
    1 interaction

    Avoid/Use Alternative

    rucaparib + quetiapine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quinidine (antiarrhythmic)
  • Rubraca (rucaparib)
    +
    quinidine (antiarrhythmic)
    1 interaction

    Avoid/Use Alternative

    rucaparib + quinidine (antiarrhythmic)

    use alternative or monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • quinidine (CYP2D6 inhibitor)
  • Rubraca (rucaparib)
    +
    quinidine (CYP2D6 inhibitor)
    1 interaction

    Avoid/Use Alternative

    rucaparib + quinidine (CYP2D6 inhibitor)

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quinine
  • Rubraca (rucaparib)
    +
    quinine
    1 interaction

    Avoid/Use Alternative

    rucaparib + quinine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quizartinib
  • Rubraca (rucaparib)
    +
    quizartinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + quizartinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • rabies vaccine
  • Rubraca (rucaparib)
    +
    rabies vaccine
    1 interaction

    Avoid/Use Alternative

    rucaparib + rabies vaccine

    if possible, avoid immunosuppressive treatment or vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • radium Ra 223 dichloride
  • Rubraca (rucaparib)
    +
    radium Ra 223 dichloride
    1 interaction

    Avoid/Use Alternative

    rucaparib + radium Ra 223 dichloride

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • relugolix
  • Rubraca (rucaparib)
    +
    relugolix
    1 interaction

    Avoid/Use Alternative

    rucaparib + relugolix

    PROSTATE CANCER: may hold relugolix if rucaparib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before rucaparib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before rucaparib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

  • repotrectinib
  • Rubraca (rucaparib)
    +
    repotrectinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + repotrectinib

    avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • revumenib
  • Rubraca (rucaparib)
    +
    revumenib
    1 interaction

    Avoid/Use Alternative

    rucaparib + revumenib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ribociclib
  • Rubraca (rucaparib)
    +
    ribociclib
    1 interaction

    Avoid/Use Alternative

    rucaparib + ribociclib

    use alternative or monitor ECG, electrolytes, CBC: combo may incr. ribociclib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • rilpivirine
  • Rubraca (rucaparib)
    +
    rilpivirine
    1 interaction

    Avoid/Use Alternative

    rucaparib + rilpivirine

    consider alternative or monitor ECG; risk may be lower w/ IM rilpivirine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • rivaroxaban
  • Rubraca (rucaparib)
    +
    rivaroxaban
    1 interaction

    Avoid/Use Alternative

    rucaparib + rivaroxaban

    avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

  • romidepsin
  • Rubraca (rucaparib)
    +
    romidepsin
    1 interaction

    Avoid/Use Alternative

    rucaparib + romidepsin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ropeginterferon alfa-2b
  • Rubraca (rucaparib)
    +
    ropeginterferon alfa-2b
    1 interaction

    Avoid/Use Alternative

    rucaparib + ropeginterferon alfa-2b

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • selpercatinib
  • Rubraca (rucaparib)
    +
    selpercatinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + selpercatinib

    use alternative or monitor ECG, electrolytes: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • sertraline
  • Rubraca (rucaparib)
    +
    sertraline
    1 interaction

    Avoid/Use Alternative

    rucaparib + sertraline

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sevoflurane
  • Rubraca (rucaparib)
    +
    sevoflurane
    1 interaction

    Avoid/Use Alternative

    rucaparib + sevoflurane

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • simvastatin
  • Rubraca (rucaparib)
    +
    simvastatin
    1 interaction

    Avoid/Use Alternative

    rucaparib + simvastatin

    use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, BCRP-mediated transport inhibited)

  • siponimod
  • Rubraca (rucaparib)
    +
    siponimod
    1 interaction

    Avoid/Use Alternative

    rucaparib + siponimod

    consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

  • sirolimus albumin-bound
  • Rubraca (rucaparib)
    +
    sirolimus albumin-bound
    1 interaction

    Avoid/Use Alternative

    rucaparib + sirolimus albumin-bound

    avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • solifenacin
  • Rubraca (rucaparib)
    +
    solifenacin
    1 interaction

    Avoid/Use Alternative

    rucaparib + solifenacin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sorafenib
  • Rubraca (rucaparib)
    +
    sorafenib
    1 interaction

    Avoid/Use Alternative

    rucaparib + sorafenib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sotalol
  • Rubraca (rucaparib)
    +
    sotalol
    1 interaction

    Avoid/Use Alternative

    rucaparib + sotalol

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • taletrectinib
  • Rubraca (rucaparib)
    +
    taletrectinib
    1 interaction

    Avoid/Use Alternative

    rucaparib + taletrectinib

    use alternative or monitor ECG, electrolytes: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • telavancin
  • Rubraca (rucaparib)
    +
    telavancin
    1 interaction

    Avoid/Use Alternative

    rucaparib + telavancin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • tetrabenazine
  • Rubraca (rucaparib)
    +
    tetrabenazine
    1 interaction

    Avoid/Use Alternative

    rucaparib + tetrabenazine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • tizanidine
  • Rubraca (rucaparib)
    +
    tizanidine
    1 interaction

    Avoid/Use Alternative

    rucaparib + tizanidine

    use alternative or monitor BP, HR: combo may incr. tizanidine levels, risk of hypotension (including orthostasis, syncope), bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • topotecan
  • Rubraca (rucaparib)
    +
    topotecan
    1 interaction

    Avoid/Use Alternative

    rucaparib + topotecan

    avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport inhibited)

  • toremifene
  • Rubraca (rucaparib)
    +
    toremifene
    1 interaction

    Avoid/Use Alternative

    rucaparib + toremifene

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • tramadol
  • Rubraca (rucaparib)
    +
    tramadol
    1 interaction

    Avoid/Use Alternative

    rucaparib + tramadol

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trazodone
  • Rubraca (rucaparib)
    +
    trazodone
    1 interaction

    Avoid/Use Alternative

    rucaparib + trazodone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • triclabendazole
  • Rubraca (rucaparib)
    +
    triclabendazole
    1 interaction

    Avoid/Use Alternative

    rucaparib + triclabendazole

    use alternative or monitor ECG: combo may incr. triclabendazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • trifluridine
  • Rubraca (rucaparib)
    +
    trifluridine
    1 interaction

    Avoid/Use Alternative

    rucaparib + trifluridine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • triptorelin
  • Rubraca (rucaparib)
    +
    triptorelin
    1 interaction

    Avoid/Use Alternative

    rucaparib + triptorelin

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • valganciclovir
  • Rubraca (rucaparib)
    +
    valganciclovir
    1 interaction

    Avoid/Use Alternative

    rucaparib + valganciclovir

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • vandetanib
  • Rubraca (rucaparib)
    +
    vandetanib
    1 interaction

    Avoid/Use Alternative

    rucaparib + vandetanib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • vemurafenib
  • Rubraca (rucaparib)
    +
    vemurafenib
    1 interaction

    Avoid/Use Alternative

    rucaparib + vemurafenib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • venetoclax
  • Rubraca (rucaparib)
    +
    venetoclax
    1 interaction

    Avoid/Use Alternative

    rucaparib + venetoclax

    monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • vepdegestrant
  • Rubraca (rucaparib)
    +
    vepdegestrant
    1 interaction

    Avoid/Use Alternative

    rucaparib + vepdegestrant

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • vorasidenib
  • Rubraca (rucaparib)
    +
    vorasidenib
    1 interaction

    Avoid/Use Alternative

    rucaparib + vorasidenib

    use alternative: combo may incr. vorasidenib levels, risk of adverse effects (hepatic metabolism inhibited)

  • ziftomenib
  • Rubraca (rucaparib)
    +
    ziftomenib
    1 interaction

    Avoid/Use Alternative

    rucaparib + ziftomenib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ziprasidone
  • Rubraca (rucaparib)
    +
    ziprasidone
    1 interaction

    Avoid/Use Alternative

    rucaparib + ziprasidone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

  • abemaciclib
  • Rubraca (rucaparib)
    +
    abemaciclib
    1 interaction

    Monitor/Modify Tx

    rucaparib + abemaciclib

    monitor CBC: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, thrombosis risk, other adverse effects (hepatic metabolism inhibited)

  • acalabrutinib
  • Rubraca (rucaparib)
    +
    acalabrutinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + acalabrutinib

    monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • afatinib
  • Rubraca (rucaparib)
    +
    afatinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + afatinib

    decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • aficamten
  • Rubraca (rucaparib)
    +
    aficamten
    1 interaction

    Monitor/Modify Tx

    rucaparib + aficamten

    monitor cardiac fxn, incl. LVEF: combo may incr. aficamten levels, risk of cardiotoxicity, other adverse effects (hepatic metabolism inhibited)

  • albendazole
  • Rubraca (rucaparib)
    +
    albendazole
    1 interaction

    Monitor/Modify Tx

    rucaparib + albendazole

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • albuterol
  • Rubraca (rucaparib)
    +
    albuterol
    1 interaction

    Monitor/Modify Tx

    rucaparib + albuterol

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • albuterol inhaled
  • Rubraca (rucaparib)
    +
    albuterol inhaled
    1 interaction

    Monitor/Modify Tx

    rucaparib + albuterol inhaled

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • alemtuzumab
  • Rubraca (rucaparib)
    +
    alemtuzumab
    1 interaction

    Monitor/Modify Tx

    rucaparib + alemtuzumab

    monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

  • alfentanil
  • Rubraca (rucaparib)
    +
    alfentanil
    1 interaction

    Monitor/Modify Tx

    rucaparib + alfentanil

    monitor respiratory rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and respiratory depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metabolism inhibited)

  • alfuzosin
  • Rubraca (rucaparib)
    +
    alfuzosin
    1 interaction

    Monitor/Modify Tx

    rucaparib + alfuzosin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • allopurinol
  • Rubraca (rucaparib)
    +
    allopurinol
    1 interaction

    Monitor/Modify Tx

    rucaparib + allopurinol

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • aminophylline
  • Rubraca (rucaparib)
    +
    aminophylline
    1 interaction

    Monitor/Modify Tx

    rucaparib + aminophylline

    monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited, aminophylline converted to theophylline)

  • amisulpride
  • Rubraca (rucaparib)
    +
    amisulpride
    1 interaction

    Monitor/Modify Tx

    rucaparib + amisulpride

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • amitriptyline
  • Rubraca (rucaparib)
    +
    amitriptyline
    1 interaction

    Monitor/Modify Tx

    rucaparib + amitriptyline

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • anthrax vaccine
  • Rubraca (rucaparib)
    +
    anthrax vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + anthrax vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • anti-thymocyte globulin
  • Rubraca (rucaparib)
    +
    anti-thymocyte globulin
    1 interaction

    Monitor/Modify Tx

    rucaparib + anti-thymocyte globulin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • arformoterol inhaled
  • Rubraca (rucaparib)
    +
    arformoterol inhaled
    1 interaction

    Monitor/Modify Tx

    rucaparib + arformoterol inhaled

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • asciminib
  • Rubraca (rucaparib)
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    rucaparib + asciminib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • atidarsagene autotemcel
  • Rubraca (rucaparib)
    +
    atidarsagene autotemcel
    1 interaction

    Monitor/Modify Tx

    rucaparib + atidarsagene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • atorvastatin
  • Rubraca (rucaparib)
    +
    atorvastatin
    1 interaction

    Monitor/Modify Tx

    rucaparib + atorvastatin

    monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

  • auranofin
  • Rubraca (rucaparib)
    +
    auranofin
    1 interaction

    Monitor/Modify Tx

    rucaparib + auranofin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • avanafil
  • Rubraca (rucaparib)
    +
    avanafil
    1 interaction

    Monitor/Modify Tx

    rucaparib + avanafil

    monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • avapritinib
  • Rubraca (rucaparib)
    +
    avapritinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + avapritinib

    monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

  • avian influenza vaccine
  • Rubraca (rucaparib)
    +
    avian influenza vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + avian influenza vaccine

    if possible, vaccinate at least 2wk before rucaparib start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • azathioprine
  • Rubraca (rucaparib)
    +
    azathioprine
    1 interaction

    Monitor/Modify Tx

    rucaparib + azathioprine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • balsalazide
  • Rubraca (rucaparib)
    +
    balsalazide
    1 interaction

    Monitor/Modify Tx

    rucaparib + balsalazide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • baricitinib
  • Rubraca (rucaparib)
    +
    baricitinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + baricitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • benznidazole
  • Rubraca (rucaparib)
    +
    benznidazole
    1 interaction

    Monitor/Modify Tx

    rucaparib + benznidazole

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • berotralstat
  • Rubraca (rucaparib)
    +
    berotralstat
    1 interaction

    Monitor/Modify Tx

    rucaparib + berotralstat

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • betibeglogene autotemcel
  • Rubraca (rucaparib)
    +
    betibeglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    rucaparib + betibeglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • brigatinib
  • Rubraca (rucaparib)
    +
    brigatinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + brigatinib

    monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects (hepatic metabolism inhibited)

  • buprenorphine
  • Rubraca (rucaparib)
    +
    buprenorphine
    1 interaction

    Monitor/Modify Tx

    rucaparib + buprenorphine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • caffeine citrate
  • Rubraca (rucaparib)
    +
    caffeine citrate
    1 interaction

    Monitor/Modify Tx

    rucaparib + caffeine citrate

    monitor caffeine levels: combo may incr. caffeine levels, risk of adverse effects (hepatic metabolism inhibited)

  • capivasertib
  • Rubraca (rucaparib)
    +
    capivasertib
    1 interaction

    Monitor/Modify Tx

    rucaparib + capivasertib

    monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

  • carbamazepine
  • Rubraca (rucaparib)
    +
    carbamazepine
    1 interaction

    Monitor/Modify Tx

    rucaparib + carbamazepine

    monitor carbamazepine levels: combo may incr. carbamazepine levels, risk of adverse effects (hepatic metabolism inhibited)

  • celecoxib
  • Rubraca (rucaparib)
    +
    celecoxib
    1 interaction

    Monitor/Modify Tx

    rucaparib + celecoxib

    monitor bleeding s/sx: combo may incr. celecoxib levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

  • chikungunya vaccine
  • Rubraca (rucaparib)
    +
    chikungunya vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + chikungunya vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • chlorpromazine
  • Rubraca (rucaparib)
    +
    chlorpromazine
    1 interaction

    Monitor/Modify Tx

    rucaparib + chlorpromazine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • cidofovir
  • Rubraca (rucaparib)
    +
    cidofovir
    1 interaction

    Monitor/Modify Tx

    rucaparib + cidofovir

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ciprofloxacin
  • Rubraca (rucaparib)
    +
    ciprofloxacin
    1 interaction

    Monitor/Modify Tx

    rucaparib + ciprofloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clobazam
  • Rubraca (rucaparib)
    +
    clobazam
    1 interaction

    Monitor/Modify Tx

    rucaparib + clobazam

    monitor respiratory rate: combo may incr. clobazam and active metabolite levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • clomipramine
  • Rubraca (rucaparib)
    +
    clomipramine
    1 interaction

    Monitor/Modify Tx

    rucaparib + clomipramine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clozapine
  • Rubraca (rucaparib)
    +
    clozapine
    1 interaction

    Monitor/Modify Tx

    rucaparib + clozapine

    monitor CBC, ECG, BP, HR, electrolytes; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • copper histidinate
  • Rubraca (rucaparib)
    +
    copper histidinate
    1 interaction

    Monitor/Modify Tx

    rucaparib + copper histidinate

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • COVID-19 vaccine
  • Rubraca (rucaparib)
    +
    COVID-19 vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + COVID-19 vaccine

    if possible, vaccinate at least 2wk before or 3mo after rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • cyclophosphamide
  • Rubraca (rucaparib)
    +
    cyclophosphamide
    1 interaction

    Monitor/Modify Tx

    rucaparib + cyclophosphamide

    monitor CBC: combo may decr. cyclophosphamide active metabolite levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism possibly inhibited, decr. conversion to active metabolite; additive effects)

  • cyclosporine
  • Rubraca (rucaparib)
    +
    cyclosporine
    1 interaction

    Monitor/Modify Tx

    rucaparib + cyclosporine

    monitor cyclosporine levels, renal fxn: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, other adverse effects (P-gp-mediated transport inhibited)

  • dapsone
  • Rubraca (rucaparib)
    +
    dapsone
    1 interaction

    Monitor/Modify Tx

    rucaparib + dapsone

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • dasatinib
  • Rubraca (rucaparib)
    +
    dasatinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + dasatinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • deferasirox
  • Rubraca (rucaparib)
    +
    deferasirox
    1 interaction

    Monitor/Modify Tx

    rucaparib + deferasirox

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • deuruxolitinib
  • Rubraca (rucaparib)
    +
    deuruxolitinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + deuruxolitinib

    monitor CBC, thrombosis s/sx: combo may incr. deuruxolitinib levels, risk of serious infection, thromboembolism, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • deutetrabenazine
  • Rubraca (rucaparib)
    +
    deutetrabenazine
    1 interaction

    Monitor/Modify Tx

    rucaparib + deutetrabenazine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • diazepam
  • Rubraca (rucaparib)
    +
    diazepam
    1 interaction

    Monitor/Modify Tx

    rucaparib + diazepam

    monitor respiratory rate: combo may incr. diazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • diclofenac
  • Rubraca (rucaparib)
    +
    diclofenac
    1 interaction

    Monitor/Modify Tx

    rucaparib + diclofenac

    monitor bleeding s/sx; use lowest effective diclofenac dose, shortest duration of concomitant tx: combo may incr. diclofenac levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

  • digoxin
  • Rubraca (rucaparib)
    +
    digoxin
    1 interaction

    Monitor/Modify Tx

    rucaparib + digoxin

    monitor digoxin levels, HR; decr. digoxin frequency or dose by 15-30%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

  • diphtheria/tetanus vaccine
  • Rubraca (rucaparib)
    +
    diphtheria/ tetanus vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + diphtheria/ tetanus vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • diphtheria/tetanus/pertussis vaccine
  • Rubraca (rucaparib)
    +
    diphtheria/ tetanus/ pertussis vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + diphtheria/ tetanus/ pertussis vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • docetaxel
  • Rubraca (rucaparib)
    +
    docetaxel
    1 interaction

    Monitor/Modify Tx

    rucaparib + docetaxel

    monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • ebola vaccine, live
  • Rubraca (rucaparib)
    +
    ebola vaccine, live
    1 interaction

    Monitor/Modify Tx

    rucaparib + ebola vaccine, live

    consider vaccinating at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response; may increase risk of mild vesicular stomatitis virus infection (immunosuppressive effects, recombinant vaccine with vesicular stomatitis virus vector)

  • edoxaban
  • Rubraca (rucaparib)
    +
    edoxaban
    1 interaction

    Monitor/Modify Tx

    rucaparib + edoxaban

    monitor bleeding s/sx: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

  • efbemalenograstim alfa
  • Rubraca (rucaparib)
    +
    efbemalenograstim alfa
    1 interaction

    Monitor/Modify Tx

    rucaparib + efbemalenograstim alfa

    admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

  • eflapegrastim (G-CSF)
  • Rubraca (rucaparib)
    +
    eflapegrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    rucaparib + eflapegrastim (G-CSF)

    admin. eflapegrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

  • elivaldogene autotemcel
  • Rubraca (rucaparib)
    +
    elivaldogene autotemcel
    1 interaction

    Monitor/Modify Tx

    rucaparib + elivaldogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • enfortumab vedotin
  • Rubraca (rucaparib)
    +
    enfortumab vedotin
    1 interaction

    Monitor/Modify Tx

    rucaparib + enfortumab vedotin

    if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (P-gp-mediated transport inhibited)

  • eplerenone
  • Rubraca (rucaparib)
    +
    eplerenone
    1 interaction

    Monitor/Modify Tx

    rucaparib + eplerenone

    monitor potassium: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • escitalopram
  • Rubraca (rucaparib)
    +
    escitalopram
    1 interaction

    Monitor/Modify Tx

    rucaparib + escitalopram

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • etuvetidigene autotemcel
  • Rubraca (rucaparib)
    +
    etuvetidigene autotemcel
    1 interaction

    Monitor/Modify Tx

    rucaparib + etuvetidigene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • everolimus
  • Rubraca (rucaparib)
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    rucaparib + everolimus

    TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • exagamglogene autotemcel
  • Rubraca (rucaparib)
    +
    exagamglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    rucaparib + exagamglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • fedratinib
  • Rubraca (rucaparib)
    +
    fedratinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + fedratinib

    monitor CBC, LFTs: combo may incr. fedratinib levels, risk of myelosuppression, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • felodipine
  • Rubraca (rucaparib)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    rucaparib + felodipine

    monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metabolism inhibited)

  • fentanyl
  • Rubraca (rucaparib)
    +
    fentanyl
    1 interaction

    Monitor/Modify Tx

    rucaparib + fentanyl

    monitor respiratory rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • filgrastim (G-CSF)
  • Rubraca (rucaparib)
    +
    filgrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    rucaparib + filgrastim (G-CSF)

    admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

  • finerenone
  • Rubraca (rucaparib)
    +
    finerenone
    1 interaction

    Monitor/Modify Tx

    rucaparib + finerenone

    monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • fingolimod
  • Rubraca (rucaparib)
    +
    fingolimod
    1 interaction

    Monitor/Modify Tx

    rucaparib + fingolimod

    monitor ECG overnight during fingolimod initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • flibanserin
  • Rubraca (rucaparib)
    +
    flibanserin
    1 interaction

    Monitor/Modify Tx

    rucaparib + flibanserin

    monitor BP: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metabolism inhibited)

  • fluconazole
  • Rubraca (rucaparib)
    +
    fluconazole
    1 interaction

    Monitor/Modify Tx

    rucaparib + fluconazole

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • flucytosine
  • Rubraca (rucaparib)
    +
    flucytosine
    1 interaction

    Monitor/Modify Tx

    rucaparib + flucytosine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fluphenazine
  • Rubraca (rucaparib)
    +
    fluphenazine
    1 interaction

    Monitor/Modify Tx

    rucaparib + fluphenazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fluvastatin
  • Rubraca (rucaparib)
    +
    fluvastatin
    1 interaction

    Monitor/Modify Tx

    rucaparib + fluvastatin

    monitor CK, myopathy sx: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, BCRP-mediated transport inhibited)

  • formoterol inhaled
  • Rubraca (rucaparib)
    +
    formoterol inhaled
    1 interaction

    Monitor/Modify Tx

    rucaparib + formoterol inhaled

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fosphenytoin
  • Rubraca (rucaparib)
    +
    fosphenytoin
    1 interaction

    Monitor/Modify Tx

    rucaparib + fosphenytoin

    monitor phenytoin levels: combo may incr. fosphenytoin levels, risk of adverse effects (hepatic metabolism inhibited)

  • fostamatinib
  • Rubraca (rucaparib)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + fostamatinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fostemsavir
  • Rubraca (rucaparib)
    +
    fostemsavir
    1 interaction

    Monitor/Modify Tx

    rucaparib + fostemsavir

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • gemtuzumab ozogamicin
  • Rubraca (rucaparib)
    +
    gemtuzumab ozogamicin
    1 interaction

    Monitor/Modify Tx

    rucaparib + gemtuzumab ozogamicin

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • gepirone
  • Rubraca (rucaparib)
    +
    gepirone
    1 interaction

    Monitor/Modify Tx

    rucaparib + gepirone

    monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • glimepiride
  • Rubraca (rucaparib)
    +
    glimepiride
    1 interaction

    Monitor/Modify Tx

    rucaparib + glimepiride

    monitor glucose: combo may incr. glimepiride levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

  • granisetron
  • Rubraca (rucaparib)
    +
    granisetron
    1 interaction

    Monitor/Modify Tx

    rucaparib + granisetron

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • Haemophilus b vaccine
  • Rubraca (rucaparib)
    +
    Haemophilus b vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + Haemophilus b vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • hepatitis A vaccine
  • Rubraca (rucaparib)
    +
    hepatitis A vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + hepatitis A vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • hepatitis B vaccine
  • Rubraca (rucaparib)
    +
    hepatitis B vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + hepatitis B vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • human papillomavirus vaccine
  • Rubraca (rucaparib)
    +
    human papillomavirus vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + human papillomavirus vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • hydroxyurea
  • Rubraca (rucaparib)
    +
    hydroxyurea
    1 interaction

    Monitor/Modify Tx

    rucaparib + hydroxyurea

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ibrutinib
  • Rubraca (rucaparib)
    +
    ibrutinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + ibrutinib

    consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • influenza vaccine
  • Rubraca (rucaparib)
    +
    influenza vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + influenza vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • interferon beta 1a
  • Rubraca (rucaparib)
    +
    interferon beta 1a
    1 interaction

    Monitor/Modify Tx

    rucaparib + interferon beta 1a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • interferon beta 1b
  • Rubraca (rucaparib)
    +
    interferon beta 1b
    1 interaction

    Monitor/Modify Tx

    rucaparib + interferon beta 1b

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • interferon gamma 1b
  • Rubraca (rucaparib)
    +
    interferon gamma 1b
    1 interaction

    Monitor/Modify Tx

    rucaparib + interferon gamma 1b

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • irinotecan
  • Rubraca (rucaparib)
    +
    irinotecan
    1 interaction

    Monitor/Modify Tx

    rucaparib + irinotecan

    monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (BCRP-mediated transport inhibited)

  • ixabepilone
  • Rubraca (rucaparib)
    +
    ixabepilone
    1 interaction

    Monitor/Modify Tx

    rucaparib + ixabepilone

    monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metabolism inhibited)

  • Japanese encephalitis vaccine
  • Rubraca (rucaparib)
    +
    Japanese encephalitis vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + Japanese encephalitis vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • lapatinib
  • Rubraca (rucaparib)
    +
    lapatinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + lapatinib

    monitor ECG: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (BCRP-mediated transport inhibited, additive effects)

  • leflunomide
  • Rubraca (rucaparib)
    +
    leflunomide
    1 interaction

    Monitor/Modify Tx

    rucaparib + leflunomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lemborexant
  • Rubraca (rucaparib)
    +
    lemborexant
    1 interaction

    Monitor/Modify Tx

    rucaparib + lemborexant

    adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • lenvatinib
  • Rubraca (rucaparib)
    +
    lenvatinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + lenvatinib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • levalbuterol inhaled
  • Rubraca (rucaparib)
    +
    levalbuterol inhaled
    1 interaction

    Monitor/Modify Tx

    rucaparib + levalbuterol inhaled

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lidocaine
  • Rubraca (rucaparib)
    +
    lidocaine
    1 interaction

    Monitor/Modify Tx

    rucaparib + lidocaine

    monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metabolism inhibited)

  • linezolid
  • Rubraca (rucaparib)
    +
    linezolid
    1 interaction

    Monitor/Modify Tx

    rucaparib + linezolid

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lomitapide
  • Rubraca (rucaparib)
    +
    lomitapide
    1 interaction

    Monitor/Modify Tx

    rucaparib + lomitapide

    ADULT PATIENTS: if patient on stable rucaparib dose and starting lomitapide, adjust max lomitapide dose to 30 mg/day; if patient on stable lomitapide dose and starting rucaparib, decr. lomitapide dose by 50% and adjust max lomitapide dose to 30 mg/day; PEDIATRIC PATIENTS: if patient on stable rucaparib dose and starting lomitapide, adjust max lomitapide dose to 10 mg/day if 2-10 yo or 20 mg/day if 11-17 yo; if patient on stable lomitapide dose and starting rucaparib, decr. lomitapide dose by 50% and adjust max lomitapide dose to 10 mg/day if 2-10 yo or 20 mg/day if 11-17 yo: combo may incr. lomitapide levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lovastatin
  • Rubraca (rucaparib)
    +
    lovastatin
    1 interaction

    Monitor/Modify Tx

    rucaparib + lovastatin

    monitor CK, myopathy sx: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

  • lovotibeglogene autotemcel
  • Rubraca (rucaparib)
    +
    lovotibeglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    rucaparib + lovotibeglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • lumateperone
  • Rubraca (rucaparib)
    +
    lumateperone
    1 interaction

    Monitor/Modify Tx

    rucaparib + lumateperone

    monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • lurasidone
  • Rubraca (rucaparib)
    +
    lurasidone
    1 interaction

    Monitor/Modify Tx

    rucaparib + lurasidone

    monitor ECG: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • lurbinectedin
  • Rubraca (rucaparib)
    +
    lurbinectedin
    1 interaction

    Monitor/Modify Tx

    rucaparib + lurbinectedin

    monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • lymphocyte immune globulin, anti-thymocyte globulin
  • Rubraca (rucaparib)
    +
    lymphocyte immune globulin, anti-thymocyte globulin
    1 interaction

    Monitor/Modify Tx

    rucaparib + lymphocyte immune globulin, anti-thymocyte globulin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • marnetegragene autotemcel
  • Rubraca (rucaparib)
    +
    marnetegragene autotemcel
    1 interaction

    Monitor/Modify Tx

    rucaparib + marnetegragene autotemcel

    monitor CBC, bleeding signs/symptoms: combo may incr. risk of myelosuppression (additive effects)

  • mavacamten
  • Rubraca (rucaparib)
    +
    mavacamten
    1 interaction

    Monitor/Modify Tx

    rucaparib + mavacamten

    monitor cardiac fxn, incl. LVEF; if patient stable on rucaparib tx, initiate mavacamten at 5 mg qd; if adding short-term (<1wk) rucaparib tx to existing mavacamten tx, hold mavacamten until rucaparib D/C; if adding longer-term (>1wk) rucaparib tx, decr. mavacamten dose as follows for at least 12wk: decr. mavacamten 15 mg qd to 10 mg qd; decr. mavacamten 10 mg qd to 5 mg qd; decr. mavacamten 5 mg qd to 2.5 mg qd; do not start rucaparib tx if on mavacamten 2.5 mg qd: combo may incr. mavacamten levels, risk of heart failure, other adverse effects (hepatic metabolism inhibited)

  • mavorixafor
  • Rubraca (rucaparib)
    +
    mavorixafor
    1 interaction

    Monitor/Modify Tx

    rucaparib + mavorixafor

    monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited, additive effects)

  • mefloquine
  • Rubraca (rucaparib)
    +
    mefloquine
    1 interaction

    Monitor/Modify Tx

    rucaparib + mefloquine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • meningococcal vaccine
  • Rubraca (rucaparib)
    +
    meningococcal vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + meningococcal vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • mercaptopurine
  • Rubraca (rucaparib)
    +
    mercaptopurine
    1 interaction

    Monitor/Modify Tx

    rucaparib + mercaptopurine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mesalamine
  • Rubraca (rucaparib)
    +
    mesalamine
    1 interaction

    Monitor/Modify Tx

    rucaparib + mesalamine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mesalamine rectal
  • Rubraca (rucaparib)
    +
    mesalamine rectal
    1 interaction

    Monitor/Modify Tx

    rucaparib + mesalamine rectal

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • methotrexate
  • Rubraca (rucaparib)
    +
    methotrexate
    1 interaction

    Monitor/Modify Tx

    rucaparib + methotrexate

    monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (BCRP-mediated transport inhibited, additive effects)

  • metronidazole
  • Rubraca (rucaparib)
    +
    metronidazole
    1 interaction

    Monitor/Modify Tx

    rucaparib + metronidazole

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • midazolam
  • Rubraca (rucaparib)
    +
    midazolam
    1 interaction

    Monitor/Modify Tx

    rucaparib + midazolam

    monitor respiratory rate: combo may incr. midazolam and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • midostaurin
  • Rubraca (rucaparib)
    +
    midostaurin
    1 interaction

    Monitor/Modify Tx

    rucaparib + midostaurin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • mirtazapine
  • Rubraca (rucaparib)
    +
    mirtazapine
    1 interaction

    Monitor/Modify Tx

    rucaparib + mirtazapine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • mitoxantrone
  • Rubraca (rucaparib)
    +
    mitoxantrone
    1 interaction

    Monitor/Modify Tx

    rucaparib + mitoxantrone

    monitor CBC, cardiac fxn, incl. LVEF: combo may incr. mitoxantrone levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (BCRP-mediated transport inhibited)

  • morphine
  • Rubraca (rucaparib)
    +
    morphine
    1 interaction

    Monitor/Modify Tx

    rucaparib + morphine

    monitor respiratory rate, consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

  • mycophenolate mofetil
  • Rubraca (rucaparib)
    +
    mycophenolate mofetil
    1 interaction

    Monitor/Modify Tx

    rucaparib + mycophenolate mofetil

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mycophenolic acid
  • Rubraca (rucaparib)
    +
    mycophenolic acid
    1 interaction

    Monitor/Modify Tx

    rucaparib + mycophenolic acid

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • nifedipine
  • Rubraca (rucaparib)
    +
    nifedipine
    1 interaction

    Monitor/Modify Tx

    rucaparib + nifedipine

    monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • nimodipine
  • Rubraca (rucaparib)
    +
    nimodipine
    1 interaction

    Monitor/Modify Tx

    rucaparib + nimodipine

    monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • nisoldipine
  • Rubraca (rucaparib)
    +
    nisoldipine
    1 interaction

    Monitor/Modify Tx

    rucaparib + nisoldipine

    monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • ofloxacin
  • Rubraca (rucaparib)
    +
    ofloxacin
    1 interaction

    Monitor/Modify Tx

    rucaparib + ofloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • olodaterol inhaled
  • Rubraca (rucaparib)
    +
    olodaterol inhaled
    1 interaction

    Monitor/Modify Tx

    rucaparib + olodaterol inhaled

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • olsalazine
  • Rubraca (rucaparib)
    +
    olsalazine
    1 interaction

    Monitor/Modify Tx

    rucaparib + olsalazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • osilodrostat
  • Rubraca (rucaparib)
    +
    osilodrostat
    1 interaction

    Monitor/Modify Tx

    rucaparib + osilodrostat

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pegfilgrastim (G-CSF)
  • Rubraca (rucaparib)
    +
    pegfilgrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    rucaparib + pegfilgrastim (G-CSF)

    admin. pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

  • peginterferon alfa 2a
  • Rubraca (rucaparib)
    +
    peginterferon alfa 2a
    1 interaction

    Monitor/Modify Tx

    rucaparib + peginterferon alfa 2a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • peginterferon beta 1a
  • Rubraca (rucaparib)
    +
    peginterferon beta 1a
    1 interaction

    Monitor/Modify Tx

    rucaparib + peginterferon beta 1a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pemigatinib
  • Rubraca (rucaparib)
    +
    pemigatinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + pemigatinib

    monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • phenytoin
  • Rubraca (rucaparib)
    +
    phenytoin
    1 interaction

    Monitor/Modify Tx

    rucaparib + phenytoin

    monitor phenytoin levels: combo may incr. phenytoin levels, risk of toxicity (hepatic metabolism inhibited)

  • pitavastatin
  • Rubraca (rucaparib)
    +
    pitavastatin
    1 interaction

    Monitor/Modify Tx

    rucaparib + pitavastatin

    monitor CK, myopathy sx: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited)

  • pneumococcal vaccine
  • Rubraca (rucaparib)
    +
    pneumococcal vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + pneumococcal vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • poliovirus vaccine
  • Rubraca (rucaparib)
    +
    poliovirus vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + poliovirus vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • pomalidomide
  • Rubraca (rucaparib)
    +
    pomalidomide
    1 interaction

    Monitor/Modify Tx

    rucaparib + pomalidomide

    monitor CBC: combo may incr. pomalidomide levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • posaconazole
  • Rubraca (rucaparib)
    +
    posaconazole
    1 interaction

    Monitor/Modify Tx

    rucaparib + posaconazole

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pravastatin
  • Rubraca (rucaparib)
    +
    pravastatin
    1 interaction

    Monitor/Modify Tx

    rucaparib + pravastatin

    monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited)

  • proguanil
  • Rubraca (rucaparib)
    +
    proguanil
    1 interaction

    Monitor/Modify Tx

    rucaparib + proguanil

    monitor CBC, especially if concomitant renal impairment: combo may incr. proguanil levels, risk of myelosuppression, other adverse effects; may decr. proguanil active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite; additive effects)

  • promethazine
  • Rubraca (rucaparib)
    +
    promethazine
    1 interaction

    Monitor/Modify Tx

    rucaparib + promethazine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • propranolol
  • Rubraca (rucaparib)
    +
    propranolol
    1 interaction

    Monitor/Modify Tx

    rucaparib + propranolol

    monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

  • pyrimethamine
  • Rubraca (rucaparib)
    +
    pyrimethamine
    1 interaction

    Monitor/Modify Tx

    rucaparib + pyrimethamine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ranolazine
  • Rubraca (rucaparib)
    +
    ranolazine
    1 interaction

    Monitor/Modify Tx

    rucaparib + ranolazine

    monitor ECG: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited, additive effects)

  • rasagiline
  • Rubraca (rucaparib)
    +
    rasagiline
    1 interaction

    Monitor/Modify Tx

    rucaparib + rasagiline

    adjust max rasagiline dose to 0.5 mg/day: combo may incr. rasagiline levels, risk of adverse effects (hepatic metabolism inhibited)

  • red yeast rice
  • Rubraca (rucaparib)
    +
    red yeast rice
    1 interaction

    Monitor/Modify Tx

    rucaparib + red yeast rice

    monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, red yeast rice contains varying amounts of lovastatin)

  • respiratory syncytial virus vaccine
  • Rubraca (rucaparib)
    +
    respiratory syncytial virus vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + respiratory syncytial virus vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • ribavirin
  • Rubraca (rucaparib)
    +
    ribavirin
    1 interaction

    Monitor/Modify Tx

    rucaparib + ribavirin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • rifabutin
  • Rubraca (rucaparib)
    +
    rifabutin
    1 interaction

    Monitor/Modify Tx

    rucaparib + rifabutin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • riociguat
  • Rubraca (rucaparib)
    +
    riociguat
    1 interaction

    Monitor/Modify Tx

    rucaparib + riociguat

    consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (BCRP-mediated transport inhibited)

  • rituximab
  • Rubraca (rucaparib)
    +
    rituximab
    1 interaction

    Monitor/Modify Tx

    rucaparib + rituximab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ropinirole
  • Rubraca (rucaparib)
    +
    ropinirole
    1 interaction

    Monitor/Modify Tx

    rucaparib + ropinirole

    consider decr. ropinirole dose: combo may incr. ropinirole levels, risk of adverse effects (hepatic metabolism inhibited)

  • rosuvastatin
  • Rubraca (rucaparib)
    +
    rosuvastatin
    1 interaction

    Monitor/Modify Tx

    rucaparib + rosuvastatin

    monitor CK, myopathy sx: combo may incr. rosuvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited)

  • ruxolitinib topical
  • Rubraca (rucaparib)
    +
    ruxolitinib topical
    1 interaction

    Monitor/Modify Tx

    rucaparib + ruxolitinib topical

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sacituzumab govitecan
  • Rubraca (rucaparib)
    +
    sacituzumab govitecan
    1 interaction

    Monitor/Modify Tx

    rucaparib + sacituzumab govitecan

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • salmeterol inhaled
  • Rubraca (rucaparib)
    +
    salmeterol inhaled
    1 interaction

    Monitor/Modify Tx

    rucaparib + salmeterol inhaled

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sargramostim (GM-CSF)
  • Rubraca (rucaparib)
    +
    sargramostim (GM-CSF)
    1 interaction

    Monitor/Modify Tx

    rucaparib + sargramostim (GM-CSF)

    admin. sargramostim >24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

  • sarilumab
  • Rubraca (rucaparib)
    +
    sarilumab
    1 interaction

    Monitor/Modify Tx

    rucaparib + sarilumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • satralizumab
  • Rubraca (rucaparib)
    +
    satralizumab
    1 interaction

    Monitor/Modify Tx

    rucaparib + satralizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sebetralstat
  • Rubraca (rucaparib)
    +
    sebetralstat
    1 interaction

    Monitor/Modify Tx

    rucaparib + sebetralstat

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sirolimus
  • Rubraca (rucaparib)
    +
    sirolimus
    1 interaction

    Monitor/Modify Tx

    rucaparib + sirolimus

    monitor sirolimus levels, CBC: combo may incr. sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • smallpox/mpox vaccine, live
  • Rubraca (rucaparib)
    +
    smallpox/ mpox vaccine, live
    1 interaction

    Monitor/Modify Tx

    rucaparib + smallpox/ mpox vaccine, live

    consider vaccinating at least 4wk before or 3mo after rucaparib: combo may result in inadequate vaccine response (immunosuppressive effects)

  • stiripentol
  • Rubraca (rucaparib)
    +
    stiripentol
    1 interaction

    Monitor/Modify Tx

    rucaparib + stiripentol

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • succimer
  • Rubraca (rucaparib)
    +
    succimer
    1 interaction

    Monitor/Modify Tx

    rucaparib + succimer

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sufentanil
  • Rubraca (rucaparib)
    +
    sufentanil
    1 interaction

    Monitor/Modify Tx

    rucaparib + sufentanil

    monitor respiratory rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • sulfasalazine
  • Rubraca (rucaparib)
    +
    sulfasalazine
    1 interaction

    Monitor/Modify Tx

    rucaparib + sulfasalazine

    monitor CBC: combo may incr. sulfasalazine levels, risk of myelosuppression, other adverse effects; may decr. IBD tx efficacy (gut BCRP-mediated transport inhibited, additive effects)

  • sunitinib
  • Rubraca (rucaparib)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + sunitinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • tacrolimus
  • Rubraca (rucaparib)
    +
    tacrolimus
    1 interaction

    Monitor/Modify Tx

    rucaparib + tacrolimus

    monitor tacrolimus levels, ECG, electrolytes, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • tadalafil
  • Rubraca (rucaparib)
    +
    tadalafil
    1 interaction

    Monitor/Modify Tx

    rucaparib + tadalafil

    monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • talazoparib
  • Rubraca (rucaparib)
    +
    talazoparib
    1 interaction

    Monitor/Modify Tx

    rucaparib + talazoparib

    monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

  • tazemetostat
  • Rubraca (rucaparib)
    +
    tazemetostat
    1 interaction

    Monitor/Modify Tx

    rucaparib + tazemetostat

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • temsirolimus
  • Rubraca (rucaparib)
    +
    temsirolimus
    1 interaction

    Monitor/Modify Tx

    rucaparib + temsirolimus

    monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • tenofovir alafenamide
  • Rubraca (rucaparib)
    +
    tenofovir alafenamide
    1 interaction

    Monitor/Modify Tx

    rucaparib + tenofovir alafenamide

    if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport inhibited)

  • tenofovir disoproxil
  • Rubraca (rucaparib)
    +
    tenofovir disoproxil
    1 interaction

    Monitor/Modify Tx

    rucaparib + tenofovir disoproxil

    monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport inhibited)

  • teplizumab
  • Rubraca (rucaparib)
    +
    teplizumab
    1 interaction

    Monitor/Modify Tx

    rucaparib + teplizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • terbutaline
  • Rubraca (rucaparib)
    +
    terbutaline
    1 interaction

    Monitor/Modify Tx

    rucaparib + terbutaline

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • teriflunomide
  • Rubraca (rucaparib)
    +
    teriflunomide
    1 interaction

    Monitor/Modify Tx

    rucaparib + teriflunomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • thalidomide
  • Rubraca (rucaparib)
    +
    thalidomide
    1 interaction

    Monitor/Modify Tx

    rucaparib + thalidomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • theophylline
  • Rubraca (rucaparib)
    +
    theophylline
    1 interaction

    Monitor/Modify Tx

    rucaparib + theophylline

    monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited)

  • tick-borne encephalitis vaccine
  • Rubraca (rucaparib)
    +
    tick-borne encephalitis vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + tick-borne encephalitis vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • tocilizumab
  • Rubraca (rucaparib)
    +
    tocilizumab
    1 interaction

    Monitor/Modify Tx

    rucaparib + tocilizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tofacitinib
  • Rubraca (rucaparib)
    +
    tofacitinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + tofacitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tolterodine
  • Rubraca (rucaparib)
    +
    tolterodine
    1 interaction

    Monitor/Modify Tx

    rucaparib + tolterodine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • tolvaptan
  • Rubraca (rucaparib)
    +
    tolvaptan
    1 interaction

    Monitor/Modify Tx

    rucaparib + tolvaptan

    consider decr. tolvaptan dose: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metabolism inhibited)

  • torsemide
  • Rubraca (rucaparib)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    rucaparib + torsemide

    monitor renal fxn, BP: combo may incr. torsemide levels, risk of nephrotoxicity, hypotension, other adverse effects (hepatic metabolism inhibited)

  • triazolam
  • Rubraca (rucaparib)
    +
    triazolam
    1 interaction

    Monitor/Modify Tx

    rucaparib + triazolam

    monitor respiratory rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • trimethoprim
  • Rubraca (rucaparib)
    +
    trimethoprim
    1 interaction

    Monitor/Modify Tx

    rucaparib + trimethoprim

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • typhoid vaccine
  • Rubraca (rucaparib)
    +
    typhoid vaccine
    1 interaction

    Monitor/Modify Tx

    rucaparib + typhoid vaccine

    if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • ubrogepant
  • Rubraca (rucaparib)
    +
    ubrogepant
    1 interaction

    Monitor/Modify Tx

    rucaparib + ubrogepant

    limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

  • upadacitinib
  • Rubraca (rucaparib)
    +
    upadacitinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + upadacitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • valbenazine
  • Rubraca (rucaparib)
    +
    valbenazine
    1 interaction

    Monitor/Modify Tx

    rucaparib + valbenazine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • valproic acid
  • Rubraca (rucaparib)
    +
    valproic acid
    1 interaction

    Monitor/Modify Tx

    rucaparib + valproic acid

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • vancomycin
  • Rubraca (rucaparib)
    +
    vancomycin
    1 interaction

    Monitor/Modify Tx

    rucaparib + vancomycin

    VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

  • vardenafil
  • Rubraca (rucaparib)
    +
    vardenafil
    1 interaction

    Monitor/Modify Tx

    rucaparib + vardenafil

    monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited, additive effects)

  • venlafaxine
  • Rubraca (rucaparib)
    +
    venlafaxine
    1 interaction

    Monitor/Modify Tx

    rucaparib + venlafaxine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • vilanterol inhaled
  • Rubraca (rucaparib)
    +
    vilanterol inhaled
    1 interaction

    Monitor/Modify Tx

    rucaparib + vilanterol inhaled

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • vinblastine
  • Rubraca (rucaparib)
    +
    vinblastine
    1 interaction

    Monitor/Modify Tx

    rucaparib + vinblastine

    monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • vincristine
  • Rubraca (rucaparib)
    +
    vincristine
    1 interaction

    Monitor/Modify Tx

    rucaparib + vincristine

    monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • vinorelbine
  • Rubraca (rucaparib)
    +
    vinorelbine
    1 interaction

    Monitor/Modify Tx

    rucaparib + vinorelbine

    monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • voclosporin
  • Rubraca (rucaparib)
    +
    voclosporin
    1 interaction

    Monitor/Modify Tx

    rucaparib + voclosporin

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • voriconazole
  • Rubraca (rucaparib)
    +
    voriconazole
    1 interaction

    Monitor/Modify Tx

    rucaparib + voriconazole

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • warfarin
  • Rubraca (rucaparib)
    +
    warfarin
    1 interaction

    Monitor/Modify Tx

    rucaparib + warfarin

    monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

  • zanubrutinib
  • Rubraca (rucaparib)
    +
    zanubrutinib
    1 interaction

    Monitor/Modify Tx

    rucaparib + zanubrutinib

    monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • zidovudine
  • Rubraca (rucaparib)
    +
    zidovudine
    1 interaction

    Monitor/Modify Tx

    rucaparib + zidovudine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

Caution Advised

  • abrocitinib
  • Rubraca (rucaparib)
    +
    abrocitinib
    1 interaction

    Caution Advised

    rucaparib + abrocitinib

    caution advised: combo may incr. abrocitinib and active metabolite levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited)

  • acitretin
  • Rubraca (rucaparib)
    +
    acitretin
    1 interaction

    Caution Advised

    rucaparib + acitretin

    caution advised: combo may incr. risk of photosensitivity reaction (additive effects)

  • caffeine
  • Rubraca (rucaparib)
    +
    caffeine
    1 interaction

    Caution Advised

    rucaparib + caffeine

    caution advised: combo may incr. caffeine levels, risk of adverse effects (hepatic metabolism inhibited)

  • cariprazine
  • Rubraca (rucaparib)
    +
    cariprazine
    1 interaction

    Caution Advised

    rucaparib + cariprazine

    caution advised: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

  • carisoprodol
  • Rubraca (rucaparib)
    +
    carisoprodol
    1 interaction

    Caution Advised

    rucaparib + carisoprodol

    caution advised: combo may incr. carisoprodol levels, decr. active metabolite meprobamate levels, alter risk of adverse effects and efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

  • clopidogrel
  • Rubraca (rucaparib)
    +
    clopidogrel
    1 interaction

    Caution Advised

    rucaparib + clopidogrel

    caution advised: combo may decr. clopidogrel active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion of clopidogrel to active metabolite)

  • cobimetinib
  • Rubraca (rucaparib)
    +
    cobimetinib
    1 interaction

    Caution Advised

    rucaparib + cobimetinib

    caution advised: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • conivaptan
  • Rubraca (rucaparib)
    +
    conivaptan
    1 interaction

    Caution Advised

    rucaparib + conivaptan

    caution advised: combo may incr. conivaptan levels, risk of overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metabolism inhibited)

  • daridorexant
  • Rubraca (rucaparib)
    +
    daridorexant
    1 interaction

    Caution Advised

    rucaparib + daridorexant

    caution advised: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • darolutamide
  • Rubraca (rucaparib)
    +
    darolutamide
    1 interaction

    Caution Advised

    rucaparib + darolutamide

    if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • dihydroergotamine
  • Rubraca (rucaparib)
    +
    dihydroergotamine
    1 interaction

    Caution Advised

    rucaparib + dihydroergotamine

    caution advised: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • duloxetine
  • Rubraca (rucaparib)
    +
    duloxetine
    1 interaction

    Caution Advised

    rucaparib + duloxetine

    caution advised: combo may incr. duloxetine levels, risk of adverse effects (hepatic metabolism inhibited)

  • elinzanetant
  • Rubraca (rucaparib)
    +
    elinzanetant
    1 interaction

    Caution Advised

    rucaparib + elinzanetant

    caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • ergotamine
  • Rubraca (rucaparib)
    +
    ergotamine
    1 interaction

    Caution Advised

    rucaparib + ergotamine

    caution advised: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • glecaprevir
  • Rubraca (rucaparib)
    +
    glecaprevir
    1 interaction

    Caution Advised

    rucaparib + glecaprevir

    caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

  • melatonin
  • Rubraca (rucaparib)
    +
    melatonin
    1 interaction

    Caution Advised

    rucaparib + melatonin

    caution advised: combo may incr. melatonin levels, risk of adverse effects (hepatic metabolism inhibited)

  • methoxsalen
  • Rubraca (rucaparib)
    +
    methoxsalen
    1 interaction

    Caution Advised

    rucaparib + methoxsalen

    caution advised: combo may incr. risk of photosensitivity reaction (additive effects)

  • methylergonovine
  • Rubraca (rucaparib)
    +
    methylergonovine
    1 interaction

    Caution Advised

    rucaparib + methylergonovine

    caution advised: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • naldemedine
  • Rubraca (rucaparib)
    +
    naldemedine
    1 interaction

    Caution Advised

    rucaparib + naldemedine

    caution advised: combo may incr. naldemedine levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • palovarotene
  • Rubraca (rucaparib)
    +
    palovarotene
    1 interaction

    Caution Advised

    rucaparib + palovarotene

    caution advised: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)

  • pexidartinib
  • Rubraca (rucaparib)
    +
    pexidartinib
    1 interaction

    Caution Advised

    rucaparib + pexidartinib

    caution advised: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • pibrentasvir
  • Rubraca (rucaparib)
    +
    pibrentasvir
    1 interaction

    Caution Advised

    rucaparib + pibrentasvir

    caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

  • ramelteon
  • Rubraca (rucaparib)
    +
    ramelteon
    1 interaction

    Caution Advised

    rucaparib + ramelteon

    caution advised: combo may incr. ramelteon levels, risk of adverse effects (hepatic metabolism inhibited)

  • riluzole
  • Rubraca (rucaparib)
    +
    riluzole
    1 interaction

    Caution Advised

    rucaparib + riluzole

    caution advised: combo may incr. riluzole levels, risk of adverse effects (hepatic metabolism inhibited)

  • rilzabrutinib
  • Rubraca (rucaparib)
    +
    rilzabrutinib
    1 interaction

    Caution Advised

    rucaparib + rilzabrutinib

    caution advised: combo may incr. rilzabrutinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • roflumilast
  • Rubraca (rucaparib)
    +
    roflumilast
    1 interaction

    Caution Advised

    rucaparib + roflumilast

    caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • roflumilast topical
  • Rubraca (rucaparib)
    +
    roflumilast topical
    1 interaction

    Caution Advised

    rucaparib + roflumilast topical

    caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • seladelpar
  • Rubraca (rucaparib)
    +
    seladelpar
    1 interaction

    Caution Advised

    rucaparib + seladelpar

    caution advised if also combined with OATP1B1 and/or OATP1B3 inhibitor: combo may incr. seladelpar levels, risk of adverse effects (BCRP-mediated transport inhibited)

  • sirolimus topical
  • Rubraca (rucaparib)
    +
    sirolimus topical
    1 interaction

    Caution Advised

    rucaparib + sirolimus topical

    caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metabolism inhibited)

  • verapamil
  • Rubraca (rucaparib)
    +
    verapamil
    1 interaction

    Caution Advised

    rucaparib + verapamil

    caution advised: combo may incr. verapamil levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

  • verteporfin
  • Rubraca (rucaparib)
    +
    verteporfin
    1 interaction

    Caution Advised

    rucaparib + verteporfin

    caution advised: combo may incr. risk of photosensitivity reaction (additive effects)

  • zolmitriptan
  • Rubraca (rucaparib)
    +
    zolmitriptan
    1 interaction

    Caution Advised

    rucaparib + zolmitriptan

    caution advised: combo may incr. zolmitriptan levels, risk of adverse effects (hepatic metabolism inhibited)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@3c131e0
  • AML
  • myelodysplastic syndrome
  • thrombocytopenia
  • anemia
  • neutropenia
  • febrile neutropenia
  • infection, serious
  • hemorrhage
  • QT prolongation
  • arrhythmia
  • cardiac ischemia
  • venous thromboembolism
  • renal failure
  • hand-foot syndrome
  • hypersensitivity reaction

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@4f77c497
  • asthenia
  • nausea
  • constipation
  • appetite decr.
  • diarrhea
  • vomiting
  • rash
  • musculoskeletal pain
  • abdominal pain
  • dysgeusia
  • dyspnea
  • anemia
  • headache
  • peripheral edema
  • dizziness
  • thrombocytopenia
  • ALT or AST elevated
  • infection
  • stomatitis
  • weight decr.
  • neutropenia
  • insomnia
  • photosensitivity
  • peripheral neuropathy
  • fever
  • dyspepsia
  • depression
  • cough
  • acute kidney injury
  • Cr incr.
  • phosphate decr.
  • lymphocytes decr.
  • sodium decr.
  • alk phos incr.
  • glucose incr.
  • calcium incr.

Safety/Monitoring .

Monitoring Parameters
pregnancy test at baseline; CBC with diff at baseline, then qmo

Pregnancy/Lactation .

Pregnancy

Clinical Summary

weigh risk/benefit during pregnancy; no human data available; risk of embryo-fetal death based on animal data at 0.04x recommended human dose and drug's mechanism of action

Individuals of Reproductive Potential

obtain pregnancy test before tx start; avoid pregnancy by using effective contraception during tx and x6mo after D/C in patients of childbearing potential; use effective contraception, including with pregnant partners, during tx and x3mo after D/C in male patients; avoid semen donation during tx and x3mo after D/C

Lactation

Clinical Summary

avoid breastfeeding during tx and x2wk after D/C; no human data available to assess risk of infant harm, though possible drug excretion into milk based on drug properties; no human data available to assess effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@62d7aead

Metabolism: for rucaparib: liver; CYP450: 1A2, 2D6 (primary), 3A4 substrate

Excretion: for rucaparib: urine, feces; Half-life: 26h

Subclass: PARP Inhibitors

Mechanism of Action
for rucaparib: inhibits poly (ADP-ribose) polymerase (PARP) enzymes and increases PARP-DNA complex formation, resulting in DNA damage and cell death

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Clovis Oncology, Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@72fba43e

DEA/FDA: Rx

Retail Price

Estimated prices only. For current pricing, visit GoodRx.

oral tablet:

  • 200 mg (120 ea): $16,810.00
  • 300 mg (120 ea): $16,809.00

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information